Trademarkia Logo

Canada

C$
Trademark Search in Canada
AEVI GENOMIC MEDICINE

View On IC.GC.CA

AEVI GENOMIC MEDICINE
REGISTERED

on 25 Oct 2019

Last Applicant/ Owned by

AEVI GENOMIC MEDICINE INC.

435 Devon Park Dr., Suite 715Wayne, PA 19087

US

Serial Number

1833164 filed on 18th Apr 2017

Registration Number

TMA1060673 registered on 25th Oct 2019

Registration expiry Date

25th Oct 2029

Correspondent Address

SMART & BIGGAR LP

1000 RUE DE LA GAUCHETIERE OUESTBUREAU 3300MONTREAL

QUÉBEC

CA

H3B4W5

AEVI GENOMIC MEDICINE

Trademark usage description

reagents for research purposes, namely, diagnostic reagents for medical-scientific research use, chemical reagents for medical-scientific research use Read More

Classification Information

Class [001]
Reagents for research purposes, namely, diagnostic reagents for medical-scientific research use, chemical reagents for medical-scientific research use; laboratory assay kits for research purposes

Classification kind code

10

Class [005]
Pharmaceutical preparations for the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; biological and chemical preparations for humans and animals for the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; antibodies for humans and animals for the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; proteins, enzymes, and peptides for humans and animals for the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; small molecule drugs for the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; medical diagnostic reagents; clinical diagnostic reagents, and clinical diagnostic assays; therapeutic agents for use in the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; immunotherapeutics and immunologics for use in the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; viral, retroviral, and non-viral vectors for use in the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; human vaccines; adjuvants for use in the treatment of pediatric onset and rare and orphan disorders, namely, central nervous system disorders, namely, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Senile Dementia, Attention Deficit disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Autism, Asperger's Syndrome, Migraine, Encephalitis, Epilepsy, Cerebral Palsy, autoimmune disorders, and malignant diseases, namely, cancer, lymphoma, leukemia; biological materials, namely, genetically modified autologous tissue implants, intended to produce proteins for therapeutic uses

Classification kind code

10

Class [042]
Medical research; pharmaceutical drug development services; testing, inspection, research, and development of pharmaceutical preparations for gene therapy

Classification kind code

10

Class [044]
Medical services, namely, harvesting tissue from a patient, genetically modifying that tissue and then reintroducing it into the same patient for therapeutic purposes; medical services

Classification kind code

10

Mark Details

Serial Number

1833164

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 190
on 20th Jun 2019		Registration Pending
Submitted for opposition 42
on 13th Mar 2019		Advertised
Submitted for opposition 26
on 21st Feb 2019		Approved
Submitted for opposition 27
on 2th Jan 2019		Approval Notice Sent
Submitted for opposition 15
on 1st Oct 2018		Correspondence Created
Submitted for opposition 22
on 16th Mar 2018		Search Recorded
Submitted for opposition 20
on 16th Mar 2018		Examiner's First Report
Submitted for opposition 31
on 25th Apr 2017		Formalized
Submitted for opposition 1
on 19th Apr 2017		Created
Submitted for opposition 30
on 18th Apr 2017		Filed